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In Bangladesh, induced abortion is allowed only to save a 
woman’s life; however, in 1979, the government officially 
approved menstrual regulation (MR) as one of the meth-
ods of the family planning program to reduce morbidity 
and mortality related to unsafe abortion.1 MR, a procedure 
to regulate the menstrual cycle after a missed menstrual 
period, is available free of charge to women at risk of preg-
nancy for up to 12 weeks since last menstrual period; the 
procedure is typically performed using manual vacuum 
aspiration at government hospitals, and health and fam-
ily welfare clinics.1 Because pregnancy is not confirmed 
prior to the procedure, MR is not regulated by the penal 
code restricting abortion.2 Despite MR’s availability, in 
2014, an estimated 1,194,000 pregnancy terminations in 
Bangladesh took place outside of the formal health care 
sector—nearly three times the number of clinic-based 
MRs—and an estimated 384,000 women experienced com-
plications from their abortion procedure.3
In February 2013, the first combination medica-
tion abortion regimen of mifepristone and misoprostol 
was accepted by the National Drug Administration of 
Bangladesh and came onto the market as an alternative to 
surgical MR; a second brand was approved and became 
available later that year. In 2015, medication MR was 
incorporated into the national family planning program to 
be administered by trained doctors or mid-level providers 
up to nine weeks since last menstrual period.4 Although 
the combination regimen has therefore been available by 
prescription from private and nongovernmental organiza-
tion (NGO) clinics and drug sellers* since 2013,5 penetra-
tion of the product into the public health system has been 
somewhat slow.6
However, the drug misoprostol on its own has been 
increasingly used since the late 1980s as a safe alterna-
tive to surgical methods for terminating a first-trimester 
pregnancy and is now recommended in the World Health 
Organization’s abortion guidelines for this indication 
where mifepristone is not available.7,8 The practice of self-
administration of drug shop–procured misoprostol alone 
as an abortifacient has been documented in settings other 
than Bangladesh and has been termed a “harm reduction 
approach,” providing women with a safer alternative to 
clandestine methods of abortion when legal services are 
not available.9 In Latin America, this practice has con-
tributed to declines in rates of severe abortion-related 
*In this article, we use the terms drug seller and drug shop to refer to 
any individual and outlet selling medications, whether or not they are 
trained or registered to do so.
CONTEXT: In Bangladesh, prior to the availability of the approved combination regimen of mifepristone and 
misoprostol for menstrual regulation (MR), drug seller provision of misoprostol-only regimens for MR without a 
prescription was widespread but service quality was poor. Examining provider practices relating to misoprostol-
only provision in Bangladesh may increase understanding of misoprostol use and provision in other low-resource, 
legally restrictive settings.
METHODS: In 2013–2014, a countrywide cross-sectional knowledge, attitudes and practice survey was 
conducted among 777 randomly selected drug sellers; data were analyzed descriptively. Logistic regression was 
used to test the associations between exposure to three interventions designed to improve drug seller practice 
(nongovernmental organization [NGO]–led training, a call center and in-shop training from pharmaceutical 
company representatives) and correct knowledge of the misoprostol-only MR regimen.
RESULTS: Almost all (97%) of the drug sellers reported providing medications intended for MR; misoprostol-only 
was more commonly sold than the combination regimen (96% vs. 26%). Nine percent had received NGO–led 
training, 62% had received in-shop training from a pharmaceutical company representative and 27% had used 
the call center. Overall, 19% of drug sellers knew the correct misoprostol-only MR regimen, and 74% wanted more 
information about this regimen. Correct regimen knowledge was positively associated with receipt of NGO training 
and call center utilization (odds ratios, 2.0 and 1.9, respectively).
CONCLUSIONS: NGO–led training and call centers should be considered in other settings in which misoprostol 
alone is provided off-label for pregnancy termination.
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complications and deaths.10,11 Misoprostol on its own is 
not an approved MR treatment in Bangladesh, but the drug 
is registered for gastric ulcer and postpartum bleeding, and 
thus can be legally sold by registered drug sellers for these 
indications with a prescription. In 2011, a mystery client 
survey conducted among 331 registered and unregistered 
drug shops from two districts of Bangladesh showed that 
misoprostol-only was commonly available over the coun-
ter for MR.5
In many low-resource settings, including Bangladesh, 
drug sellers or pharmacy workers play a key role in repro-
ductive health care,12–14 and are often preferred by clients 
because of their convenience, discretion and accessibil-
ity.15,16 In Bangladesh, the Directorate General of Drug 
Administration, the body responsible for issuing licenses 
to sell medicines, reported that there were 97,357 regis-
tered pharmacies in the country in 2014.17 To qualify for 
registration, a pharmacy or medicine shop must have an 
employee who has a minimum of a secondary school cer-
tificate in science, has completed an 80-hour dispensing 
training with the Pharmacy Council of Bangladesh and 
has passed the related exam.18 In addition to the registered 
providers, there were an estimated 30,000–100,000 unreg-
istered drug sellers in 2014.5,17,18
Because misoprostol alone is not registered for use 
for MR in Bangladesh, no instructions are printed on its 
packet for this purpose and clients are reliant on drug sell-
ers’ advice for appropriate dosage. However, drug seller 
provision of the misoprostol-only regimen for MR without 
a prescription (or for medication abortion in other set-
tings) is associated with poor quality provider knowledge 
and patient counseling.19 The mystery client survey con-
ducted in Bangladesh in 2011 found that only 7% of drug 
sellers advised an effective misoprostol-only MR dosage.5 
Recommending an ineffective misoprostol dose may result 
in failed or incomplete MR procedures.20,21
Using a postintervention, national, cross-sectional sur-
vey conducted in 2013–2014, this study aims to docu-
ment drug seller knowledge and self-reported provision 
of misoprostol-only and mifepristone plus misoprostol 
medications across the country shortly after the combi-
nation pack was introduced. The heterogeneous provider 
landscape of licensed and unlicensed drug sellers, self- 
medication and widespread availability of the misoprostol-
only method of medication abortion as an alternative to 
legal abortion is not unique to Bangladesh; many countries 
of Africa have similar features. Hence, an examination of 
provider knowledge and practices relating to misoprostol-
only provision in Bangladesh provides important baseline 
data for the country, but may be valuable to elucidate 
misoprostol use and provision in other low-resource, 
legally restrictive settings.
We also report on three nationwide program strate-
gies introduced in Bangladesh prior to 2013 that aimed 
to improve drug seller knowledge and end-user care 
for women seeking misoprostol-only MR treatments, 
and investigate whether exposure to such strategies is 
associated with drug seller knowledge. Although misopro-
stol alone is not an approved method for MR within the 
Bangladesh family planning program, it is commonly used 
for this purpose, and the practice is widely referred to as 
MR at the community level.22 This term was therefore used 
in the intervention and survey tools; the language is also 
consistent with other research on this topic.5,23
Exposure Interventions
Research from low- and middle-income countries has 
shown that introducing training programs for drug sellers 
can improve their reproductive health care knowledge and 
practice, including in relation to medication abortion pro-
vision.19 Between 2008 and 2010, Marie Stopes Bangladesh 
ran in-shop training sessions with drug sellers from 
approximately 4,000 shops surrounding all of the Marie 
Stopes clinics located in 62 out of 64 Bangladeshi districts. 
Outreach trainers (university graduates, most with medi-
cal or pharmacy qualifications) visited drug shops selling 
misoprostol at least once per month to give drug sellers 
verbal information on the most effective misoprostol-only 
regimen for MR.† They also provided information on side 
effects, complications and referral options.
The second initiative was the establishment of a call 
center in 2010 by Marie Stopes Bangladesh to improve 
knowledge of the correct use of medications for MR 
among users and those providing it. The call center, 
which was still operating at the time of this study, was 
open 24 hours, seven days per week, and was manned 
in shifts by physicians at Marie Stopes Bangladesh until 
2011, when three paramedics were hired and trained as 
dedicated call center operators. The number was not toll 
free, but call center operators would return missed calls. 
From 2012, the call center phone number was printed on 
the packet and foil of one misoprostol product, and the 
service and phone number were advertised in drug shops 
on posters, flyers, wallet-sized cards, stickers and hang-
ing cards. From September 2011, call center operators 
were trained to record who the caller was (e.g., provider, 
MR user, husband), and from July 2012, they recorded 
the reason for the call and other basic information.
The third initiative, “pharmaceutical company detail-
ing,” consisted of in-pharmacy training delivered by rep-
resentatives of a national pharmaceutical company when 
they visited drug shops to distribute branded misopros-
tol and other drugs; this activity began in 2011 and was 
ongoing at the time of the study. The representatives 
were trained to give verbal information to drug sellers to 
whom they sold misoprostol, including on correct use of 
the product for MR (e.g., eligibility, most effective regimen, 
side effects and complications).
We are not aware of any other interventions to improve 
drug sellers’ knowledge of using misoprostol for MR 
†The most effective misoprostol-only regimen for MR is defined as three 
doses of 800μg misoprostol, with three hours between each dose, taken 
vaginally, buccally or sublingually up to nine weeks since last menstrual 
period.
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taking place at the time of the interventions included in 
this study.
METHODS
Study Setting and Design
Between November 2013 and February 2014, we conduct-
ed a cross-sectional knowledge, attitudes and practice 
survey among drug sellers from all seven geographical 
divisions of Bangladesh;‡ the study was approved by the 
Marie Stopes International Ethical Review Committee 
and the Bangladesh Medical Research Council. Because 
of the large number of unregistered drug sellers in 
Bangladesh, no complete sampling frame of drug shops 
exists. In October 2013, we obtained a list of 10,285 drug 
shops from the pharmaceutical company conducting 
the in-shop training visits. The list included the names 
and locations of all outlets in 57 of the 64 districts of 
Bangladesh that had been supplied misoprostol by the 
pharmaceutical company in the previous three months. 
We used systematic sampling to select 120 drug shops 
from each division. In each division, the total number 
of drug shops in the sampling frame was divided by 
120 to obtain a sampling interval. The drug shops were 
numbered in the order in which they were received from 
the pharmaceutical company. The first drug shop was 
selected using Excel to generate a random number, and 
the sampling interval was repeatedly added to the first 
number to obtain the remaining 119 outlets.
Field workers from Marie Stopes Bangladesh visited 
each drug shop and recruited one worker to take part 
in the survey. Drug sellers were eligible to participate if 
they had worked at the shop for six months and were 
involved in selling drugs; if more than one drug seller 
met the inclusion criteria, the owner or longest serving 
worker was selected. All participants gave verbal consent 
to participate, and confidentiality was ensured by using 
anonymous identification codes for each individual and 
shop. Because providing medications for MR without 
a prescription is not approved in Bangladesh and drug 
sellers could face negative consequences if provision with-
out a prescription was disclosed, extra care was taken to 
maintain anonymity.
Our planned sample of 120 drug shops per division 
allowed us to detect the population proportion of drug 
shops listed in our sampling frame in each division where 
the respondent knew the correct misoprostol-only regimen 
with a precision of plus or minus 10% and a significance of 
.05, under the assumption that 50% did so. Eight hundred 
and forty drug shops were selected, 120 from each divi-
sion, which allowed for a 17% refusal rate. We were able 
to locate 796 of the sampled drug shops; however, 15 of 
these had no drug seller willing to participate, and two had 
no eligible drug seller. In total, 779 drug sellers were inter-
viewed; two of these interviews were terminated midway 
through and were not included in the analysis.
‡At the time of the study, there were seven divisions in Bangladesh.
The questionnaire was developed in English, translated 
into Bengali and then back translated into English. Prior 
to the study, the questionnaire was piloted with 15 drug 
sellers in 10 urban and semi-urban pharmacies in Dhaka 
division; after piloting, minor edits were made to the ques-
tionnaire to improve clarity and translation quality.
Data Collection
A field worker interviewed each participant and recorded 
their responses on a paper questionnaire that covered 
the characteristics of the provider and the drug shop, 
including age, gender, education and type of professional 
training;§ years of experience selling misoprostol for MR; 
whether they were the owner of the drug shop; and the 
number of employees. Provision practices were assessed 
by asking respondents about the types of MR medications 
they provide and the cost, the types of advice and postcare 
they offer MR clients, the questions they ask prospective 
MR clients, perceived contraindications for provision of 
MR medications and whether they sell misoprostol for MR 
without a prescription.
The primary outcome was correct knowledge of the 
misoprostol-only regimen for MR advised in the exposure 
program interventions. The drug sellers had to demon-
strate correct knowledge of four elements: the dose in 
micrograms (tablet size and number of tablets per dose), 
number of doses, hours between each dose and at least 
one route of administration. We also asked about the max-
imum time since the last menstrual period that MR should 
be taken, and knowledge of side effects and complications. 
In addition, participants were asked whether they had 
received pharmaceutical company detailing, if they had 
used the call center, if they had participated in NGO–led 
training or if they had had any other kind of training on 
misoprostol for MR; we created a series of corresponding 
dummy indicators for each type of training.
Statistical Analysis
To document drug seller knowledge and provision prac-
tices, we analyzed the data descriptively using tabulations 
showing sample distributions and proportions. Some 
variables had missing responses, which are shown or 
described in the tables.
The bivariate analysis and regression models were 
restricted to the 746 respondents who reported selling 
misoprostol in the last three months, and only included 
the 678 observations with complete data on the outcomes 
and explanatory variables. We conducted a bivariate analy-
sis using chi-square tests to assess the associations between 
explanatory variables and the outcome, considering the 
following variables: drug shop characteristics (number of 
§In addition to the 1–2-year government diploma, professional phar-
macy training for drug sellers could include one or more government-
approved training (six-month pharmacist certificate training, 3–6-month 
local medical assistant and family planning training or three-month rural 
medical practitioner training) or training that has not been approved by 
the government, such as that provided by a pharmaceutical or social 
marketing company.
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drug sellers working at the outlet, division, number of MR 
clients per month), drug seller characteristics (age, educa-
tion, professional training, years of experience, whether 
respondent sells misoprostol for other conditions), other 
training (having ever received training or information on 
using misoprostol for MR outside of the three study inter-
ventions) and program exposure (training, pharmaceutical 
company detailing and using the call center). We used mul-
tivariable logistic regression to test associations between 
program exposure and correct knowledge of MR regimen, 
adjusting for all of the variables listed above, except respon-
dent’s gender, because the small number of females created 
cell count issues. Data were analyzed using STATA 13.0.
RESULTS
Forty-two percent of drug shops had only one employee 
(Table 1). The majority of respondents were male (99%), 
were aged 30 or older (75%) and were drug shop owners 
(88%); 60% had achieved their higher secondary certifi-
cate, and 88% had received some professional pharmacy 
training. Only 7%, however, had received one or more 
years of professional training, indicating completion of 
a government-approved pharmacy diploma or degree. 
Eighty percent had received training lasting less than a 
year, and 11% had no training. Sixty-two percent had more 
than 10 years’ experience selling drugs.
MR Provision Practices
Nearly all respondents (97%) reported that they sold 
medications for MR (Table 2). Ninety-six percent reported 
providing misoprostol-only, and 26% the combination reg-
imen. A further 29% reported that they offered hormonal 
medications (oral contraceptives, emergency contracep-
tion or medication for secondary amenorrhea) to MR cli-
ents; these are not effective for MR, but it is possible that 
some hormonal medications could cause harm if taken 
during pregnancy. Four percent reported providing other 
medication not effective for MR (such as herbal medicine 
or iron pills). When asked how they respond to a customer 
asking about MR services, 82% reported offering MR med-
ications for purchase, 30% advised clients to continue with 
their pregnancy and 82% referred clients to health facili-
ties, to medical providers or for counseling. Ninety-seven 
percent reported stocking and selling misoprostol in the 
previous three months.
Among the participants who had stocked and sold 
misoprostol in the last three months, quality of care var-
ied: Some 94% reported asking for the date of the last 
menstrual period, 44% asked questions about medical 
history or medication allergies, 36% asked about use of 
MR or emergency contraception since last menstrual 
period and 13% asked whether the end user had an IUD 
inserted. Thirty-nine percent of participants reported 
that they asked for personal details before offering MR 
medications (e.g., third-party permission or reasons for 
MR). The most common reasons stated for why a woman 
should not be given medications for MR were allergies or 
medical contraindications (62%) and length of time since 
last menstrual period (more than nine weeks, 40%; more 
than seven weeks, 25%). In terms of client follow-up, 92% 
reported providing MR clients with a phone number to call 
for more information, and 54% reported referring clients 
to a health facility if they returned with heavy bleeding, 
incomplete MR or signs of infection. Eighty-eight per-
cent reported offering family planning services post–MR. 
Among those who sold misoprostol-only for MR, 92% 
reported doing so without a prescription. The median 
number of misoprostol clients in the previous month was 
seven.
TABLE 1. Percentage distribution of drug shops and drug 
sellers participating in a knowledge, attitudes and practice 

































1–2-year government-approved diploma 7.3
Missing 1.7
No. of years in profession
<10 37.8
³10 62.2




†Includes one or more government-approved training (six-month 
pharmacist certificate training, 3–6-month local medical assistant and 
family planning training or three-month rural medical practitioner 
training) or training that has not been approved by the government, 
such as that provided by a pharmaceutical or social marketing 
company. Note: Percentages may not total 100.0 because of rounding.
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Fifty-seven percent of drug sellers had heard of the 
combination regimen, but only 37% of drug shops sold 
it (not shown). Among 290 drug shops offering the com-
bination regimen, the median estimated number sold per 
month was five. The reported mean cost of the combina-
tion regimen kits ranged from 212 Bangladesh taka (BDT; 
US$2.72) to BDT 270 (US$3.45). By comparison, each 
200μg misoprostol tablet costs an average of BDT 13.50 
(US$0.17) for the cheapest brand and BDT 15 (US$0.19) 
for the most expensive. For the full, most effective regi-
men of 12 tablets, the cost of misoprostol-only MR treat-
ment would range from BDT 162 (US$2.07) to BDT 180 
(US$2.31), cheaper than the mifepristone-misoprostol 
approved MR regimen.
Training and Knowledge
Among drug sellers who reported stocking and sell-
ing misoprostol in the previous three months, 72% had 
received one or more types of training or orientation on 
using misoprostol-only for MR (Table 3). Just 9% had 
received NGO training, 62% pharmaceutical company 
detailing and 27% had used the call center. Only 16% 
of respondents felt they had sufficient knowledge about 
using misoprostol-only for MR; 74% said they would like 
to know more about the regimen, 78% about side effects 
and complications, and 32% about when to prescribe MR 
medications.
Nineteen percent of respondents had correct knowl-
edge of the recommended misoprostol-only MR regimen. 
Fifty-two percent knew the correct dosage per dose, 34% 
knew that there should be three doses, 58% knew that 
there should be three hours between doses and 85% knew 
at least one correct administration route. Thirty percent 
identified a total dose that was lower than the optimal 
regimen, and 29% identified a higher dose. In terms of 
eligibility, only 11% of respondents correctly stated the 
maximum time since the last menstrual period recom-
mended in Bangladesh for MR with medication (nine 
weeks); 48% stated a lower limit, 36% stated 10–12 weeks 
and 2% stated more than 12 weeks. Forty-one percent of 
respondents identified five potential side effects, and 53% 
identified two serious complications.
Multivariable Findings
In models adjusted for division, drug shop and drug seller 
characteristics, those who had received NGO–led training 
or used the call center had increased odds of knowledge 
of correct regimen (odds ratios, 2.0 and 1.9, respectively—
Table 4). The odds of correct knowledge were lower in 
Khulna, Chittagong, Rangpur and Barisal than in Dhaka 
(0.2–0.5), and higher among those who had sold misopro-
stol for MR for two or more years than among those with 
less experience (1.7). We explored whether receiving more 
than one intervention or receiving particular combinations 
of interventions improved knowledge using interaction 
terms in the logistic regression models, but found no evi-
dence to support these types of effects.
DISCUSSION
This national cross-sectional study of Bangladeshi drug 
sellers’ knowledge and provision provides a vital snapshot 
of on-the-ground provision practices of different drugs for 
MR in 2013–2014, just as the mifepristone-misoprostol 
regimen started to become available legally. The main find-
ings highlight that despite misoprostol-only being sold 
for MR almost universally (and in most cases, without a 
prescription), drug sellers were generally confused about 
the most effective regimen to induce MR, the appropriate 




Provides medications for MR†
Any MR medication 97.0
Mifepristone-misoprostol combination 26.3
Misoprostol-only 95.5
Hormonal medications not effective for MR (oral contraceptive/emergency 
contraception/Gynaecosid)
29.0
Other medications not effective for MR‡ 4.3
Advice given when client asks about MR services†
Offers MR medications 82.0
Advises them to continue with pregnancy 29.5
Refers to health facility/medical provider/counseling 82.0
Refers to traditional health provider 7.9
Stocked and sold misoprostol in past three mos. (for any indication 
including MR)
97.0
Sells misoprostol for other conditions (not MR-related) 54.7
RESPONDENTS WHO STOCKED AND SOLD MISOPROSTOL IN LAST THREE  
MOS. (N=746)
Questions asked before offering MR medications†
Date of LMP 94.2
Allergy to medications/medical history 44.4
Whether end-user tried any MR/emergency contraception since LMP 36.3
Whether IUD inserted 13.0
Any personal details (permission from third party, background, reason for 
wanting MR) 
39.0
Conditions when would not provide MR medications†
No reasons 1.5
Pregnancy too advanced (>9 weeks since LMP) 40.4
Pregnancy too advanced (>7 weeks since LMP) 24.8
Lactating mother 28.8
Medical history/allergy/possible drug reaction/fever or infection 61.5
IUD inserted 17.7
Post–MR care†
Gives phone number to call for more information§ 91.8
Refers to health facility in cases of heavy bleeding/incomplete MR/infection 53.5
Offers family planning services after misoprostol for MR§ 87.8
Selling practices and reported purchasing
Sells misoprostol for MR without prescription 92.1
Mean price of lowest- and highest-cost brands for 200μg of misoprostol††,‡‡ US$0.17–0.19
Median no. of MR clients who bought misoprostol in the previous mo.§§ 7 (4–10)
RESPONDENTS WHO SELL COMBINATION REGIMEN (N=290)
Selling practices and reported purchasing
Mean price of combination brand 1†† US$3.45 (0.98)
Mean price of combination brand 2†† US$2.72 (1.32)
Median estimated no. of MR clients who purchase the combination regimen  
per mo.§
5 (3–10)
†Multiple responses were allowed. ‡Includes herbal medicine, iron pills, worm tablets, folic acid and 
paracetamol. §Missing one value. ††Price calculated using mean exchange rate for 2013 of 78.1 
Bangladesh taka to US$1. ‡‡Missing 20 values. §§Missing 33 values. Notes: MR=menstrual regulation. 
LMP=last menstrual period. Figures in parentheses are standard deviations or interquartile ranges.
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period of time to use MR after the last menstrual period 
and contraindications. This is largely consistent with 
results from a systematic review of pharmacy medication 
abortion provision, which found that sales of MR medi-
cines without a prescription in low-income settings were 
common.19 For five years prior to the survey, interventions 
had been conducted in Bangladesh to educate formal- and 
informal-sector drug sellers about the correct off-label use 
of misoprostol for MR. Despite NGO–led training, phar-
maceutical company detailing and call center support for 
off-label use of misoprostol for uterine evacuation, drug 
sellers typically did not know how to use misoprostol cor-
rectly. Although knowledge of the correct, most effective 
regimen for using misoprostol-only for MR was higher 
than the 7% reported in a 2011 mystery client study,5 it 
was still low (19%). The heterogeneous picture of drug 
sellers’ knowledge and provision of misoprostol presented 
here is relevant for understanding medication abortion 
practices in other low-income settings where legal medica-
tion abortion is not currently available and off-label use of 
misoprostol-only is the most widely used treatment, such 
as in many countries in Latin America and Sub-Saharan 
Africa.19
A worrying finding was that many drug sellers did not 
know the length of time after the last menstrual period 
that misoprostol should be used (nine weeks is recom-
mended in this context, and second-trimester use requires 
a reduced dose),8 and many lacked knowledge of the side 
effects and possible complications associated with miso-
prostol. Fewer than half reported asking such key screen-
ing questions for MR as date of the last menstrual period, 
medical history, use of MR or emergency contraception 
since the last menstrual period and whether the end user 
had an IUD inserted. A further concern was that a third 
of drug sellers identified a dose lower than that recom-
mended by WHO at the time of the study,8 which could 
lead to higher rates of incomplete MR20,21 and potentially 
greater abortion-related morbidity, as women may be past 
the time limit for clinic-based MR and may then turn to 
less-safe methods to complete their MR. Similarly, low 
knowledge of the upper gestational limit could lead to 
administration of MR medications at later gestational ages, 
which is also associated with higher rates of incomplete 
procedures.24
The misoprostol-only regimen for MR was sold by 
more than three times as many drug sellers as the offi-
cially approved combination regimen, which is perhaps 
unsurprising since the first combination pack brand was 
registered just nine months before data collection started. 
Slightly more than half of drug sellers had heard of at least 
one brand of the combination regimen, suggesting that 
drug seller awareness may be an important barrier to the 
uptake of mifepristone-misoprostol. Affordability could 
also affect use; while the cost of the combination regimen 
was not much higher than the most effective misoprostol- 
only regimen, one-third of drug sellers reported that 
they sell the misoprostol-only MR treatment at a subop-
timal dose (fewer than 12 tablets), which lowers its cost. 
In 2014–2015, a study conducted in three districts of 
Bangladesh also found that both regimens were still being 
used, but awareness and use of the combination pack had 
increased. The study had two parts—first, in a face-to-face 
TABLE 3. Proportion of drug sellers who stocked and sold misoprostol in the last 
three months, by measures of training on misoprostol for menstrual regulation and 




On misoprostol for MR
Received training, detailing or information from any organization (including  
call center)
71.5
Received nongovernmental organization–led training 9.0
Received pharmaceutical company detailing 61.8
Used call center† 26.5
Received other training 9.5
Feel they have enough information† 16.2
Would like more information about
Misoprostol regimen 74.0
Knowing when to prescribe MR medications 32.0
Side effects/complications 77.5
Legal issues 30.3




















Vaginal, buccal, or sublingual (correct answer) 85.4
Oral (swallowed) or rectal 14.6
Total misoprostol dose (dosage per dose x number of doses)††
<2,400μg 29.7
2,400μg (correct answer) 33.4
>2,400μg 29.1
Don’t know 5.1
Eligibility (maximum time since last menstrual period that medication MR  
should be taken)‡‡
1–8 weeks 48.4
9 weeks (correct answer) 10.5
10–12 weeks 35.7
>12 weeks 1.9
Identified five potential side effects of misoprostol correctly§§ 41.2
Identified two serious complications of misoprostol correctly†‡ 53.2
†Missing one value. ‡Defined as knowing the correct dosage per dose (800), number of doses (3), 
hours between doses (3) and at least one route of administration (buccal, sublingual or vaginal). 
§Missing 10 values. ††Missing 20 values. ‡‡Missing 27 values. §§From the following list: pain, 
nausea/vomiting, headache, vertigo, bleeding, fever/chills and weakness. †‡Infection/fever and 
prolonged or heavy bleeding.
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TABLE 4. Percentage distribution of drug sellers, by selected characteristics, according to knowledge of misoprostol-only 
menstrual regulation regimen, and odds ratios (and 95% confidence intervals) from multivariable logistic regression 
analyses assessing the associations between correct knowledge and selected drug seller and drug shop characteristics









Received nongovernmental organization–led training
No (ref) 82.6 17.4 1.00 1.00
Yes 67.2 32.8 2.31 (1.32–4.06)** 1.96 (1.03–3.72)*
Received pharmaceutical company detailing
No (ref) 83.7 16.3 1.00 1.00
Yes 79.6 20.4 1.31 (0.87–1.97) 1.27 (0.80–2.00)
Used call center
No (ref) 83.6 16.4 1.00 1.00
Yes 74.3 25.7 1.77 (1.17–2.66)** 1.86 (1.15–2.99)*
Received other training
No (ref) 80.2 19.8 1.00 1.00
Yes 90.5 9.5 0.43 (0.18–1.01) 0.48 (0.18–1.20)
No. of workers
1 (ref) 79.7 20.3 1.00 1.00
2 81.7 18.4 0.88 (0.57–1.38) 0.87 (0.53–1.43)
³3 82.8 17.2 0.81 (0.50–1.33) 0.97 (0.54–1.75)
Division
Dhaka (ref) 70.4 29.6 1.00 1.00
Khulna 83.2 16.8 0.48 (0.24–0.95)* 0.43 (0.21–0.90)*
Chittagong 91.5 8.5 0.22 (0.91–0.54)** 0.19 (0.07–0.49)**
Rangpur 92.5 7.5 0.19 (0.08–0.47)*** 0.22 (0.09–0.58)**
Rajshahi 71.8 28.2 0.93 (0.51–1.72) 0.86 (0.44–1.69)
Sylhet 76.8 23.2 0.72 (0.38–1.37) 0.76 (0.38–1.52)
Barisal 83.9 16.0 0.45 (0.23–0.89)* 0.45 (0.22–0.93)*
No. of customers sold misoprostol for MR per mo.
<5 (ref) 80.3 19.7 1.00 1.00
³5 81.8 18.3 0.91 (0.62–1.34) 0.72 (0.47–1.13)
Age
<30 (ref) 79.2 20.8 1.00 1.00
30–39 81.9 18.1 0.84 (0.52–1.36) 0.89 (0.51–1.56)
³40 81.6 18.5 0.86 (0.52–1.42) 1.08 (0.59–1.99)
Education
£secondary (ref) 81.0 19.0 1.00 1.00
Higher secondary certificate 78.7 21.3 1.16 (0.75–1.79) 1.17 (0.73–1.88)
³bachelor’s 84.7 15.3 0.77 (0.46–1.29) 0.89 (0.51–1.58)
Professional pharmacy training
None (ref) 75.7 24.3 1.00 1.00
<1 year 82.5 17.5 0.66 (0.37–1.19) 0.66 (0.33–1.31)
1–2-year government-approved diploma 72.9 27.1 1.16 (0.50–2.68) 1.25 (0.48–3.26)
No. of years in profession
<10 (ref) 78.5 21.5 1.00 1.00
³10 82.6 17.4 0.77 (0.52–1.14) 0.67 (0.41–1.10)
No. of years selling misoprostol for MR
<2 (ref) 84.4 15.6 1.00 1.00
³2 79.6 20.4 1.39 (0.90–2.14) 1.65 (1.01–2.70)*
Owner of drug shop
No (ref) 81.5 18.5 1.00 1.00
Yes 78.2 21.8 1.23 (0.69–2.18) 1.14 (0.54–2.39)
Sells misoprostol for other conditions
No (ref) 75.8 24.2 1.00 1.00
Yes 85.2 14.8 0.54 (0.37–0.80)** 0.69 (0.45–1.07)
*p<.05. **p<.01. ***p<.001. Notes: MR=menstrual regulation. ref=reference group. Percentages may not total 100.0 because of rounding.
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survey, 86% and 78% of pharmacy workers mentioned 
misoprostol and the combination pack, respectively, as a 
medication for MR.6 In the second part, mystery clients vis-
ited pharmacies to ask for medications to regulate their or 
someone else’s menstruation; 51% were sold misoprostol 
alone and 69% the combination pack.6 The survey found 
that 54% of those sold the combination pack were given 
the recommended dosage; information on misoprostol 
dosage or training was not available.
It is encouraging that use of a call center and NGO–led 
training were associated with greater knowledge of the 
correct misoprostol-only regimen among drug sellers. 
This study joins a growing body of evidence indicating 
that interventions with pharmacy workers, either through 
pharmaceutical company detailing or dedicated training 
sessions,19 can improve accessibility, knowledge and atti-
tudes toward medication abortion and may be of use in 
contexts in which the combination pack is not available. 
Successful interventions among pharmacists have also 
been shown to improve care quality and coverage of emer-
gency contraception provision.25 In Bangladesh, drug sell-
ers would ideally refer clients to legal providers who offer 
a comprehensive package of care, including post–MR fam-
ily planning counseling and services. However, barriers to 
clinic services are likely to remain, and effective training of 
drug sellers could operate as a harm reduction strategy to 
ensure that where medication MR is happening without 
a prescription, it is done so safely. Key information to be 
conveyed to drug sellers includes awareness of the com-
bination pack, the gestational limit for using medications 
for MR, possible complications and referral options. The 
correct misoprostol-only regimen for MR should also be 
disseminated if this option continues to be widely used, 
which is possibly because of its lower cost; however, prior-
ity should now be given to increasing access to the com-
bination pack, given its higher effectiveness and lower 
likelihood of incorrect use.
A number of issues should be considered when plan-
ning interventions to support drug seller provision of MR 
medications in this setting where outlets are prolific and 
unregulated. Pharmaceutical company detailing achieved 
much greater coverage than the call center and training 
(62% vs. 27% and 9%); however, it was not associated 
with correct knowledge. Cost information was not avail-
able for all of the interventions; it is likely that the costs of 
scaling up intensive training across the estimated 210,000 
registered and unregistered drug shops operating in 
Bangladesh17 would be prohibitive. The lack of evidence of 
an effect of pharmaceutical company detailing here could 
reflect that there may be little incentive for pharmaceutical 
detailers to spend time educating drug sellers on a product 
with relatively low sales, but the approach may be worth 
exploring further, particularly given the evidence that this 
approach has been successful in improving STI services 
in Bangladesh.26 Reviews of pharmacist training inter-
ventions have concluded that education is most effective 
when part of a multifaceted approach that includes referral 
networks, printed materials, special branding and social 
marketing.27–30 Mobile phone interventions that include 
SMS services, apps or websites could also be considered; 
in other contexts, smartphones have been used effectively 
to improve health care worker education, and to help them 
support follow up and adherence to medications and to 
collect information.31
The drug sellers interviewed were aware of their knowl-
edge gaps. Nearly all reported that they needed more 
information on MR medications (particularly on the 
misoprostol-only regimen), when to prescribe medica-
tions, on side effects and on complications, which indicates 
that they may be motivated to use these types of “pull” 
strategies. It may be unrealistic, however, to expect drug 
sellers to provide comprehensive counseling to MR clients, 
given that they have little financial incentive to do so, many 
have no professional training, and a lengthy conversation 
on this topic may be inappropriate or unacceptable to the 
user in such a public setting. Future approaches could also 
be targeted to increase the information available to the end 
user and to other community health providers; SMS has 
been used in South Africa to support abortion clients to 
assess abortion completion,32 and in Cambodia, recorded 
voice message reminders linked to call-center counseling 
have increased postabortion contraceptive use.33
Limitations
The study had some limitations that need to be consid-
ered when interpreting the findings. Given the relatively 
restricted nature of MR medication provision, the survey 
responses are likely to be subject to reporting bias. Data 
such as the volume of clients, prices of medications, refer-
ral advice, and the information and drug regimen shared 
with clients may not reflect actual practices; this was 
observed in a recent study among Indian pharmacists 
where abortion practices reported in face-to-face inter-
views with pharmacy workers were different from those 
experienced during mystery client visits.34 Responses may 
also be subject to recall bias: The interventions had been 
running for a number of years prior to the interview, so the 
details of interventions accessed may not be accurate. The 
sample may also not be representative of all drug shops 
operating in Bangladesh: Through necessity, we used a 
sampling frame consisting of shops supplied with miso-
prostol by one pharmaceutical company, which may have 
overestimated the availability of the product and the type 
of pharmacy being surveyed, and underrepresented more 
informal drug shops, which purchase products through 
secondary suppliers. As the pharmaceutical company 
used for sampling delivered detailing on misoprostol use 
and complications, the respondents may have been more 
knowledgeable than a completely random sample of drug 
shops. Selection of drug shops for NGO–led training and 
pharmaceutical company detailing could have been influ-
enced by factors, such as an existing high MR demand or 
perceived capability to provide an effective service. Lastly, 
the cross-sectional design limits any causal interpretation 
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of the association between intervention exposure and 
enhanced knowledge. Unmeasured confounding may 
be an issue: Respondents who used the call center could 
have background traits such as greater conscientiousness, 
which suggests that their knowledge may have been higher 
regardless of call center use.
Conclusions
This study validates other research in Bangladesh that has 
found that drug shop provision of medications for MR 
is widespread but knowledge of correct provision prac-
tices among drug sellers is poor, and to our knowledge, 
is the first to examine interventions aimed at improving 
practice. To further reduce harm from unsafe abortion in 
Bangladesh, future efforts should aim to enhance access to 
safe, legal methods of MR, expand training of drug sellers 
through a range of strategies and explore ways to target the 
end-user directly. A more robust quasi or fully experimen-
tal evaluation of initiatives that may improve quality of MR 
services provided to women in the community is needed. 
Mystery client visits and interviews with end-users of the 
medications could be employed alongside or instead of 
face-to-face interviews to ensure impacts measured are not 
limited to knowledge but capture provision practices and 
outcomes of the procedure.
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RESUMEN
Contexto: En Bangladesh, antes de que el régimen combi-
nado de mifepristona y misoprostol fuera aprobado para la 
regulación menstrual (RM), la provisión sin receta de regí-
menes de misoprostol solo para RM por parte de vendedores 
de medicamentos estuvo muy generalizada, pero la calidad 
de servicio era deficiente. Examinar las prácticas de los pro-
veedores relacionadas con la provisión de misoprostol solo en 
Bangladesh podría aumentar la comprensión sobre el uso y la 
provisión de misoprostol en otros entornos de bajos recursos 
restringidos legalmente.
Métodos: Entre 2013 y 2014, se realizó una encuesta trans-
versal de conocimientos, actitudes y prácticas en todo el país 
entre 777 vendedores de medicamentos seleccionados al azar; 
los datos fueron analizados descriptivamente. Se utilizó regre-
sión logística para evaluar las asociaciones entre la exposición 
a tres intervenciones diseñadas para mejorar las prácticas de 
los vendedores de medicamentos (capacitación conducida por 
una organización no gubernamental [ONG], un centro de 
atención telefónica y capacitación en el negocio por parte de 
representantes de las compañías farmacéuticas), así como el 
conocimiento correcto del régimen de misoprostol solo usado 
para RM.
Resultados: Casi la totalidad (97%) de los vendedores de 
medicamentos informaron que estaban vendiendo medica-
mentos para RM; que la venta de misoprostol solo era más 
común que el régimen combinado (96% vs 26%). El nueve 
por ciento había recibido capacitación impartida por ONG, el 
62% había recibido capacitación en su negocio de un represen-
tante de una compañía farmacéutica y el 27% había utilizado 
el centro de llamadas. En general, el 19% de los vendedores 
de medicamentos conocía el régimen correcto de RM basado 
en misoprostol solo y el 74% quería más información sobre 
ese régimen. El conocimiento correcto del régimen se asoció 
positivamente con la recepción de capacitación de las ONG y 
la utilización del centro de atención telefónica (razón de pro-
babilidades, 2.0 y 1.9, respectivamente).
Conclusiones: La capacitación conducida por ONG y el uso 
del centro de atención telefónica deberían considerarse en otros 
entornos restringidos en los que el misoprostol solo se propor-
ciona sin autorización para la interrupción del embarazo.
RÉSUMÉ
Contexte: Au Bangladesh, avant la disponibilité du traite-
ment homologué au mifépristone associé au misoprostol pour 
la régulation menstruelle (RM), la prestation par les vendeurs 
de médicaments des traitements de RM au misoprostol seul 
sans ordonnance était répandue, mais la qualité du service 
était faible. L’examen des pratiques de prestation relatives à 
la fourniture de misoprostol seul au Bangladesh peut aider à 
mieux cerner l’usage et l’offre de ce médicament dans d’autres 
contextes à faibles ressources soumis à des lois restrictives.
Méthodes: En 2013–2014, une étude transversale sur les 
connaissances, les attitudes et les pratiques à l’échelle du pays 
a été menée auprès de 777 vendeurs de médicaments sélec-
tionnés aléatoirement, pour analyse descriptive des données. 
La régression logistique a servi au test des associations entre 
l’exposition à trois interventions conçues pour améliorer la 
pratique des vendeurs de médicaments (formation sous la con-
duite d’organisations non gouvernementales [ONG], établisse-
ment d’un centre d’appels et formation par des représentants 
de laboratoires pharmaceutiques) et la connaissance correcte 
du traitement de RM à base de misoprostol seul. 
Résultats: Presque tous les vendeurs de médicaments (97%) 
ont déclaré vendre des médicaments destinés à la RM. Le miso-
prostol seul était vendu plus fréquemment que le traitement 
d’association (96% vs 26%). Neuf pour cent avaient bénéficié 
d’une formation par une ONG, 62% d’une formation locale 
assurée par un représentant de laboratoire pharmaceutique 
et 27% avaient eu recours au centre d’appels. Globalement, 
19% des vendeurs avaient une connaissance correcte du traite-
ment de RM à base de misoprostol seul et 74% désiraient plus 
d’information à ce sujet. La connaissance correcte du traite-
ment était associée positivement à l’obtention d’une formation 
par une ONG et au recours au centre d’appels (RC, 2,0 et 1,9, 
respectivement).
Conclusions: La formation sous la conduite d’une ONG 
et l’établissement d’un centre d’appels doivent être envisagés 
dans d’autres contextes sujets à une législation restrictive dans 
lesquels le misoprostol seul est proposé hors indication pour 
l’interruption d’une grossesse. 
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